南京科佰生物科技有限公司
主營產(chǎn)品: atcc代理,ATCC細胞系,ATCC細胞株,ATCC細胞庫購買 |
聯(lián)系電話
南京科佰生物科技有限公司
主營產(chǎn)品: atcc代理,ATCC細胞系,ATCC細胞株,ATCC細胞庫購買 |
聯(lián)系電話
參考價 | 面議 |
更新時間:2022-07-29 10:10:40瀏覽次數(shù):813
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息,謝謝!
供貨周期 | 現(xiàn)貨 | 規(guī)格 | T-25 Flask |
---|---|---|---|
貨號 | CBP74106 | 應用領域 | 生物產(chǎn)業(yè) |
主要用途 | 僅限科研使用 |
CBP74106 | |
I. Background | |
Antibody-dependent cell-mediated phagocytosis (ADCP) is one of the important mechanisms of action for antibody drug development. FcγRIIa is the predominant Fcγ receptor involved in the ADCP process. FcγRIIa is expressed in myeloid effector cells, including macrophages and neutrophils, where it plays a role in the activation of these effector cells. Several clinical studies have studied the correlation of a FcγRIIa polymorphism (R131H) and the response to IgG1 subclass monoclonal antibodies (mAbs) such as rituximab. Engineered amino-acid substitutions in Fc-mAbs have been developed to enhance the mAb-mediated phagocytosis of tumor cells by macrophages. | |
II. Description | |
Recombinant Jurkat T cell expressing a firefly luciferase gene under the control of NFAT response elements with constitutive expression of human FcγRIIa, Histidine variant. | |
III. Introduction | |
Host Cell: | Jurkat |
Expressed gene: | FcγRIIa (H variant)-NFAT |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+400ug/ml hygromycin |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
IV. Description of Host Cell Line | |
Organism: | Human |
Tissue: | Peripheral blood |
Disease: | Childhood T acute lymphoblastic leukemia |
Morphology: | Lymphoblast |
Growth Properties: | Suspension |
Ⅴ. Representative Data | |
Figure 1:Dose response of Rituximab in ADCP Bioassay Effector Cell FcyRlla (H variant) /NFAT Reporter-Jurkat (C2),the EC50 was 21.5ng/ml. |